TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
PBLTT52CAR19 modified T cells are allogenic engineered human T cells (defined as TT52CAR19
+TCRαβ-) prepared for the treatment of CD19+ B cell leukaemia. The cells are from healthy
adult volunteer donors and are not HLA-matched. They have been transduced to express and
anti-CD19 chimeric antigen receptor (CAR19) using a lentiviral vector that also incorporates
CRISPR guides for genome editing of CD52 and TRAC loci in the presence of transiently
provided Cas9.
Recognition by TT52CAR19 T cells mediates eradication of CD19+ leukaemia and other CD19+ B
cells through T cell mediated cytotoxicity.
This study aims to apply PBLTT52CAR19 T cells to secure molecular remission in children with
relapsed/refractory B-ALL ahead of programmed allogeneic stem cell transplantation. The cells
are to be used in a time-limited manner for their anti-leukaemia effects and then depleted by
standard pre- transplant conditioning.
Phase:
Phase 1
Details
Lead Sponsor:
Great Ormond Street Hospital for Children NHS Foundation Trust